Table 1 Brief description of the three clinical trials used to evaluate the feasibility of predictive modeling for eligibility screening
Abbreviation | Trial A |
|---|---|
Full name | European Surgical Outcome Study |
Recruitment period | 1 week, April 2011 |
Department | Department of Anesthesiology |
Inclusion criteria | 1. older than 16 years |
2. admitted for elective or non-elective inpatient surgery | |
Exclusion criteria | 1. patients undergoing planned day-case surgery |
2. patients undergoing cardiac surgery, neurosurgery, radiological or obstetric procedures | |
Abbreviation | Trial B |
Full name | Sensitive polyprobe approach for improved prediction of therapy response and assessment of prognosis in colorectal cancer |
Recruitment period | 3 years, December 2009 – December 2012 |
Department | Department of surgery |
Inclusion criteria | 1. initial diagnosis of histopathologically confirmed colorectal cancer of UICC stage I-IV |
Exclusion criteria | 1. inflammatory bowel disease (Crohn’s disease, Ulcerative colitis) |
2. hereditary tumor syndromes like Familial Adenomatous polyposis (FAP), Hereditary nonpolyposis colorectal cancer (HNPCC) | |
Abbreviation | Trial C |
Full name | Prospective Randomized Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rectal Cancer |
Recruitment period | 3.5 years, July 2006 – February 2010 |
Department | Department of Radiation Oncology |
Inclusion criteria | 1. aged 18 years or older |
2. histopathologically confirmed rectal carcinoma with an inferior margin no more than 12 cm above the anal verge, as assessed by rigid proctoscopy | |
3. evidence of perirectal fat infiltration (cT3–4) or lymph-node involvement (cN+), as assessed by endorectal ultra sound, multislice CT, or MRI | |
4. Eastern Cooperative Oncology Group (ECOG) performance status 2 or lower | |
5. adequate hematological, liver, and renal function | |
Exclusion criteria | 1. metastatic disease |
2. prior radiotherapy or chemotherapy | |
3. other cancers | |
4. pregnancy or lactation | |
5. clinically significant cardiac disease | |
6. known peripheral neuropathy |